| Literature DB >> 32013056 |
Larisa Janisova1, Andrey Gruzinov2, Olga V Zaborova1,3, Nadiia Velychkivska1, Ondřej Vaněk4, Petr Chytil1, Tomáš Etrych1, Olga Janoušková1, Xiaohan Zhang5, Clement Blanchet2, Christine M Papadakis5, Dmitri I Svergun2, Sergey K Filippov6.
Abstract
The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric drug delivery system based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (pHPMA) with the most abundant proteins in human blood plasma-namely, human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen (Fbg), and apolipoprotein (Apo) E4 and A1-using a combination of small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and nuclear magnetic resonance (NMR). Through rigorous investigation, we present evidence of weak interactions between proteins and polymeric nanomedicine. Such interactions do not result in the formation of the protein corona and do not affect the efficiency of the drug delivery.Entities:
Keywords: drug delivery; pHPMA; plasma proteins; polymeric nanoparticles; stealth effect
Year: 2020 PMID: 32013056 PMCID: PMC7076460 DOI: 10.3390/pharmaceutics12020106
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Chemical structure of the N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymers bearing cholesterol (pHPMA-Chol) copolymer: Mw = 21,100 g/mol; content of cholesterol = 2.2 mol %; D = 1.14.
Figure 2Small-angle X-ray scattering (SAXS) data from solutions of different proteins (dots) and corresponding fits (solid lines) of the high-resolution Protein Data Bank (PDB) model using CRYSOL and ab initio shape reconstruction using DAMMIN, respectively: (A) pHPMA nanoparticles (NPs) (inset shows the ab initio shape reconstruction model); (B) human serum albumin (HSA); (C) fibrinogen (Fbg); (D) immunoglobulin G (IgG).
Figure 3SAXS curves from mixed solutions of pHPMA-Chol copolymer NPs with proteins at different polymer/protein ratios (experimental curve: black). Each curve was modeled as a linear combination of the curves from the two pure components measured separately (calculated curve: red): (A) pHPMA-Chol/HSA = 18/20, (B) pHPMA-Chol/IgG = 18/5, (C) pHPMA-Chol/Fbg = 18/1, and (D) pHPMA-Chol/plasma = 18/20.
Figure 4Analytical ultracentrifugation (AUC) analysis of protein binding to pHPMA-Chol NPs. Overlaid normalized sedimentation coefficient distributions of the sedimenting species are shown for individual proteins (blue lines), NPs (black line), and their mixed solutions (red lines).
Figure 51H nuclear magnetic resonance (NMR) spectrum (blue) of pHPMA-Chol in the presence of HSA and the corresponding Saturation Transfer Difference (STD NMR) spectrum (red).
Ratios of proton relaxation time (T2) for HDO (solvent) molecules and pHPMA-Chol NPs.
| c(HSA) | T2HDO(HSA)/T2HDO(HSA+NP) | T2HPMA(NP)/T2HPMA(HSA+NP) | |||
|---|---|---|---|---|---|
| 2.5 | 35/40 | 2.5 | 35/40 | ||
|
|
| 1.24 | 1.48/- | 1.1 | 1/- |
|
| 3.3 | -/4.1 | 1.3 | -/1.1 | |
Figure 6STD NMR profiles for pHPMA-Chol copolymer NPs in the presence of HSA for various protons of pHPMA-Chol copolymer.